In 1983 Congress passed the Orphan Drug Act, which gave special tax credits to pharmaceutical manufacturers that develop drugs for treating rare diseases, and delayed the date at which generic drug manufacturers can enter the market for those drugs. Why might this legislation increase aggregate surplus? Why might it lower it?